Aortic stenosis medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 13: Line 13:
==Medical Therapy==
==Medical Therapy==


* [[Hypertension]] is common in [[patients]] with [[AS]], may be a risk factor for [[AS]], and increases the total [[pressure overload]] on the [[left ventricle]] in combination with [[valve]] obstruction.<ref name="pmid31290937">{{cite journal |vauthors=Nazarzadeh M, Pinho-Gomes AC, Smith Byrne K, Canoy D, Raimondi F, Ayala Solares JR, Otto CM, Rahimi K |title=Systolic Blood Pressure and Risk of Valvular Heart Disease: A Mendelian Randomization Study |journal=JAMA Cardiol |volume=4 |issue=8 |pages=788–795 |date=August 2019 |pmid=31290937 |pmc=6624812 |doi=10.1001/jamacardio.2019.2202 |url=}}</ref>
* [[Hypertension]] is common in [[patients]] with [[AS]], may be a risk factor for [[AS]], and increases the total [[pressure overload]] on the [[left ventricle]] in combination with [[valve]] obstruction.<ref name="pmid31290937">{{cite journal |vauthors=Nazarzadeh M, Pinho-Gomes AC, Smith Byrne K, Canoy D, Raimondi F, Ayala Solares JR, Otto CM, Rahimi K |title=Systolic Blood Pressure and Risk of Valvular Heart Disease: A Mendelian Randomization Study |journal=JAMA Cardiol |volume=4 |issue=8 |pages=788–795 |date=August 2019 |pmid=31290937 |pmc=6624812 |doi=10.1001/jamacardio.2019.2202 |url=}}</ref><ref name="pmid27486164">{{cite journal |vauthors=Nielsen OW, Sajadieh A, Sabbah M, Greve AM, Olsen MH, Boman K, Nienaber CA, Kesäniemi YA, Pedersen TR, Willenheimer R, Wachtell K |title=Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS) |journal=Circulation |volume=134 |issue=6 |pages=455–68 |date=August 2016 |pmid=27486164 |doi=10.1161/CIRCULATIONAHA.115.021213 |url=}}</ref>
* 2 small [[RCTs]] have not confirmed that [[antihypertensive]] [[ medications]] may reduce the [[cardiac output]] because [[AS]] does not result in fixed [[valve]] obstruction until late stage in the disease.
* 2 small [[RCTs]] have not confirmed that [[antihypertensive]] [[ medications]] may reduce the [[cardiac output]] because [[AS]] does not result in fixed [[valve]] obstruction until late stage in the disease.
* The study of asymptomatic [[AS]] showed the association of [[hypertension]] with higher rate of [[ischemic cardiovascular]] events and a 2-fold higher [[mortality rate]] ) than  normotensive [[patients]] with [[AS]]. However, impact on progression of valve stenosis leading to [[symptoms]] requiring [[AVR]] was not observed.
* The study of asymptomatic [[AS]] showed the association of [[hypertension]] with higher rate of [[ischemic cardiovascular]] events and a 2-fold higher [[mortality rate]] ) than  normotensive [[patients]] with [[AS]]. However, impact on progression of valve stenosis leading to [[symptoms]] requiring [[AVR]] was not observed.

Revision as of 13:08, 30 June 2022



Resident
Survival
Guide

Aortic Stenosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Aortic Stenosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Cardiac Stress Test

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Cardiac Catheterization

Aortic Valve Area

Aortic Valve Area Calculation

Treatment

General Approach

Medical Therapy

Surgery

Percutaneous Aortic Balloon Valvotomy (PABV) or Aortic Valvuloplasty

Transcatheter Aortic Valve Replacement (TAVR)

TAVR vs SAVR
Critical Pathway
Patient Selection
Imaging
Evaluation
Valve Types
TAVR Procedure
Post TAVR management
AHA/ACC Guideline Recommendations

Follow Up

Prevention

Precautions and Prophylaxis

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Aortic stenosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Aortic stenosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Aortic stenosis medical therapy

CDC on Aortic stenosis medical therapy

Aortic stenosis medical therapy in the news

Blogs on Aortic stenosis medical therapy

Directions to Hospitals Treating Aortic stenosis medical therapy

Risk calculators and risk factors for Aortic stenosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Mohammed A. Sbeih, M.D. [2]; Cafer Zorkun, M.D., Ph.D. [3]; Usama Talib, BSc, MD [4] Assistant Editor-In-Chief: Kristin Feeney, B.S. [5]; Rim Halaby, M.D. [6]

Overview

While medical therapy may improve the symptoms of patients with aortic stenosis (AS), medical therapy does not prolong life expectancy. Aortic valve replacement (AVR) remains the definitive treatment of symptomatic aortic stenosis and it improves both the symptoms and life expectancy of patients with aortic stenosis. When pharmacological therapies are used, extreme caution must be taken in the administration of vasodilators as excess vasodilation may lead to hypotension, a reduction in perfusion pressure to the heart, a further decline in cardiac output and further hypotension. This downward spiral can be fatal and must be avoided at all costs.[1][2]

Medical Therapy

References

  1. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA; et al. (2008). "ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 52 (23): e1–121. doi:10.1016/j.jacc.2008.10.001. PMID 19038677.
  2. Otto CM (2006). "Valvular aortic stenosis: disease severity and timing of intervention". J Am Coll Cardiol. 47 (11): 2141–51. doi:10.1016/j.jacc.2006.03.002. PMID 16750677.
  3. Nazarzadeh M, Pinho-Gomes AC, Smith Byrne K, Canoy D, Raimondi F, Ayala Solares JR, Otto CM, Rahimi K (August 2019). "Systolic Blood Pressure and Risk of Valvular Heart Disease: A Mendelian Randomization Study". JAMA Cardiol. 4 (8): 788–795. doi:10.1001/jamacardio.2019.2202. PMC 6624812 Check |pmc= value (help). PMID 31290937.
  4. Nielsen OW, Sajadieh A, Sabbah M, Greve AM, Olsen MH, Boman K, Nienaber CA, Kesäniemi YA, Pedersen TR, Willenheimer R, Wachtell K (August 2016). "Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS)". Circulation. 134 (6): 455–68. doi:10.1161/CIRCULATIONAHA.115.021213. PMID 27486164.

Template:WH Template:WS CME Category::Cardiology